TDC
TRIL

Thompson Davis & Co’s Trillium Therapeutics Inc. TRIL Stock Holding History

Thompson Davis & Co’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,000
Closed -$45K – 1291
2014
Q4 		$45K Buy
+5,000
New +$39.1K 0.05% 303

Other funds holding TRIL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Thompson Davis & Co's TRIL Position: Q1 2015 in Review

Thompson Davis & Co sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2015, closing a stake of 5,000 shares — an estimated $45K sold.

Thompson Davis & Co first reported a position in TRIL in Q4 2014 and held it in 1 quarter. The position peaked at $45K in Q4 2014. 14 funds tracked by Wall St. Rank hold TRIL as of Q1 2015.

  • Thompson Davis & Co reported no remaining Trillium Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 5,000 Trillium Therapeutics Inc. shares in Q1 2015, an estimated $45K.
  • Thompson Davis & Co first reported a position in Trillium Therapeutics Inc. in Q4 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Trillium Therapeutics Inc. position peaked at $45K in Q4 2014.
  • 14 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.